Stock Scorecard
Stock Summary for Sarepta Therapeutics Inc (SRPT) - $17.26 as of 6/23/2026 9:34:15 PM EST
Total Score
12 out of 30
Safety Score
46 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SRPT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SRPT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SRPT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SRPT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SRPT (46 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for SRPT
Financial Details for SRPT
Company Overview |
|
|---|---|
| Ticker | SRPT |
| Company Name | Sarepta Therapeutics Inc |
| Country | USA |
| Description | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/5/2026 |
Stock Price History |
|
| Last Day Price | 17.26 |
| Price 4 Years Ago | 129.58 |
| Last Day Price Updated | 6/23/2026 9:34:15 PM EST |
| Last Day Volume | 2,259,089 |
| Average Daily Volume | 3,035,853 |
| 52-Week High | 25.32 |
| 52-Week Low | 10.42 |
| Last Price to 52 Week Low | 65.64% |
Valuation Measures |
|
| Trailing PE | 50.43 |
| Industry PE | 39.23 |
| Sector PE | 82.35 |
| 5-Year Average PE | -19.41 |
| Free Cash Flow Ratio | 3.92 |
| Industry Free Cash Flow Ratio | 35.78 |
| Sector Free Cash Flow Ratio | 32.81 |
| Current Ratio Most Recent Quarter | 4.63 |
| Total Cash Per Share | 4.40 |
| Book Value Per Share Most Recent Quarter | 14.26 |
| Price to Book Ratio | 1.23 |
| Industry Price to Book Ratio | 4.30 |
| Sector Price to Book Ratio | 21.98 |
| Price to Sales Ratio Twelve Trailing Months | 0.85 |
| Industry Price to Sales Ratio Twelve Trailing Months | 12.58 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.75 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 105,576,000 |
| Market Capitalization | 1,822,241,760 |
| Institutional Ownership | 99.08% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.26% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 2,664.00% |
| Annual Earnings Growth | -403.27% |
| Reported EPS 12 Trailing Months | 0.35 |
| Reported EPS Past Year | 3.16 |
| Reported EPS Prior Year | -5.11 |
| Net Income Twelve Trailing Months | 65,057,000 |
| Net Income Past Year | -713,410,000 |
| Net Income Prior Year | 235,239,000 |
| Quarterly Revenue Growth YOY | -1.90% |
| 5-Year Revenue Growth | 32.41% |
| Operating Margin Twelve Trailing Months | 49.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 464,450,000 |
| Total Cash Past Year | 801,282,000 |
| Total Cash Prior Year | 1,103,010,000 |
| Net Cash Position Most Recent Quarter | -373,712,000 |
| Net Cash Position Past Year | -27,692,000 |
| Long Term Debt Past Year | 828,974,000 |
| Long Term Debt Prior Year | 1,137,124,000 |
| Total Debt Most Recent Quarter | 838,162,000 |
| Equity to Debt Ratio Past Year | 0.58 |
| Equity to Debt Ratio Most Recent Quarter | 0.64 |
| Total Stockholder Equity Past Year | 1,140,622,000 |
| Total Stockholder Equity Prior Year | 1,527,742,000 |
| Total Stockholder Equity Most Recent Quarter | 1,505,102,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 106,135,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 1.01 |
| Free Cash Flow Past Year | -307,451,000 |
| Free Cash Flow Prior Year | -352,743,000 |
Options |
|
| Put/Call Ratio | 0.05 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.97 |
| MACD Signal | -0.93 |
| 20-Day Bollinger Lower Band | 14.91 |
| 20-Day Bollinger Middle Band | 18.99 |
| 20-Day Bollinger Upper Band | 23.06 |
| Beta | 0.20 |
| RSI | 34.80 |
| 50-Day SMA | 19.42 |
| 150-Day SMA | 80.04 |
| 200-Day SMA | 90.49 |
System |
|
| Modified | 6/23/2026 8:53:48 AM EST |